基础药物换用或联合注射用头孢哌酮钠舒巴坦钠对泛耐药肺炎克雷伯菌肺部感染患者病情严重程度及预后的影响观察

doi:10.3969/j.issn.1006-6233.2025.03.029

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1204 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate the influence of basic drugs combined with (or switched to) the injection of cefoperazone/sulbactam on the disease severity and prognosis of patients with extensively-drug-resistant Klebsiella pneumoniae (XDR-KP) infections. Methods: The clinical data of patients with XDR-KP infection admitted from January 2021 to June 2024 were retrospectively selected. According to different medication regimens, they were assigned into basic antibacterial drugs (basic drug group, n=54) and basic drugs combined with (or switched to) the injection of cefoperazone/sulbactam (cefoperazone/sulbactam group, n=47). After about one week of treatment, the bacterial clearance, serum inflammatory indicators including platelet count (PLT), neutrophil ratio (NEUT) and white blood cell count (WBC), and infectious markers including serum amyloid A (SAA), procalcitonin (PCT) and C-reactive protein (CRP) were compared between groups. Treatment-emergent adverse events (TEAEs) and prognosis were recorded. Results: The improvement time of clinical symptoms in the cefoperazone/sulbactam group was significantly lower than that in the basic drug group (P<0.05). After about one week of treatment, the normal rate of inflammatory indicators and clearance rate of bacterial in the cefoperazone/sulbactam group were significantly higher than those in the basic drug group (P<0.05). After about one week of treatment, the levels of inflammatory indicators (PLT, NEUT and WBC) and infectious markers (SAA, PCT and CRP) in the both groups were significantly decreased (P<0.05), and the decrease in the cefoperazone/sulbactam group was more pronounced than that in the basic drug group (P<0.05). There was no statistical difference in the TEAEs between the cefoperazone/sulbactam group and the basic drug group (9.26% vs 7.41%, P>0.05). The clinical cure rate was significantly higher in the cefoperazone/sulbactam group than the basic drug group (70.21% vs 50.00%, P<0.05), and there were no statistical differences in 30d mortality and hospital stay between groups (P>0.05). Conclusion: The effects of basic drugs combined with (or switched to) the injection of cefoperazone/sulbactam are significant in the treatment of patients with XDR-KP infection, it can control infection, relieve inflammation, and improve the prognosis of patients, and it has few adverse reactions.

Key words： Extensively-drug-resistant Klebsiella pneumoniae Cefoperazone/sulbactam Therapeutic effect Severity Prognosis

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HU Wenjie
	WANG Ruikai
	LIU Jiachang

Cite this article:

HU Wenjie,WANG Ruikai,LIU Jiachang. Influence of Basic Drugs Combined with (or Switched to) the Injection of Cefoperazone/Sulbactam on Disease Severity and Prognosis of Patients with Extensively-drug-resistant Klebsiella Pneumoniae Infection[J]. HeBei Med, 2025, 31(3): 509-513.

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2025.03.029 OR http://www.hbyxzzs.cn/EN/Y2025/V31/I3/509

[1] 李莉莎,李建辉,何斌,等.噬菌体治疗泛耐药肺炎克雷伯菌肺部感染的临床应用及效果初探[J].上海交通大学学报医学版,2021,41(9):1272-1276.
[2] Ardebili A,Izanloo A,Rastegar M.Polymyxin combination therapy for multidrug-resistant,extensively-drug resistant,and difficult-to-treat drug-resistant gram-negative infections:is it superior to polymyxin monotherapy?[J].Expert Rev Anti Infect Ther,2023,21(4):387-429.
[3] 韦华,鲁厚清,胡鑫.头孢哌酮舒巴坦钠联合替加环素治疗多重耐药肺炎克雷伯菌肺炎的临床研究[J].现代药物与临床,2023,38(12):3071-3075.
[4] Tian Y,Zhang QY,Wen LR,et al.Combined effect of polymyxin B and tigecycline to overcome heteroresistance in carbapenem-resistant Klebsiella pneumoniae[J].Microbiol Spectr,2021,9(2):152.
[5] Tumbarello M,Raffaelli F,Cascio A,et al.Compassionate use of meropenem/vaborbactam for infections caused by KPC-producing Klebsiella pneumoniae:a multicentre study[J].JAC Antimicrob Resist,2022,4(1):22.
[6] 胡永煜,吴湜,郑永贵,等.头孢哌酮-舒巴坦联合多黏菌素E等6种抗菌药物对碳青霉烯类耐药鲍曼不动杆菌体外抗菌作用研究[J].中国感染与化疗杂志,2022,22(2):189-193.
[7] Zhu Z,Zhang B,Wang Y,et al.A wide clinical spectrum of pulmonary affection in subjects with community-acquired Klebsiella pneumoniae liver abscess (CA-KPLA)[J].Infect Chemother,2023,29(1):48-54.
[8] 刘笑芬,毋海兰,范亚新,等.从药动学/药效学角度优化头孢哌酮/舒巴坦的临床给药方案[J].中国抗生素杂志,2022,47(11):1156-1161.
[9] Qian D,Zhang Y.Influence of Xuebijing injection combined with cefoperazone sodium and sulbactam sodium in treating hepatitis B-induced liver cirrhosis complicated by spontaneous bacterial peritonitis:TNF-α,IL-18,IL-6,and hepatic function[J].Am Transl Res,2021,13(4):2907-2914.
[10] Qu J,Xu J,Liu Y,et al.Real-world effectiveness of ceftazidime/avibactam versus polymyxin B in treating patients with carbapenem-resistant gram-negative bacterial infections[J].Int Antimicrob Agents,2023,62(2):106872.